Skip to Content


Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Antiparasitic Drug Use and Antiparasitic Resistance Survey

Document Details

Information about this document as published in the Federal Register.

Document Statistics
Document page views are updated periodically throughout the day and are cumulative counts for this document including its time on Public Inspection. Counts are subject to sampling, reprocessing and revision (up or down) throughout the day.
Enhanced Content

Relevant information about this document from provides additional context. This information is not part of the official Federal Register document.

Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble


Food and Drug Administration, HHS.




The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995 (the PRA).


Fax written comments on the collection of information by August 4, 2014.


To ensure that comments on the information collection are received, OMB recommends that written comments be faxed to the Office of Information and Regulatory Affairs, OMB, Attn: FDA Desk Officer, FAX: 202-395-7285, or emailed to All comments should be identified with the OMB control number 0910-NEW and title “Antiparasitic Drug Use and Antiparasitic Resistance Survey.” Also include the FDA docket number found in brackets in the heading of this document.

Start Further Info


FDA PRA Staff, Office of Operations, Food and Drug Administration, 8455 Colesville Rd., COLE-14526, Silver Spring, MD 20993-0002,

End Further Info End Preamble Start Supplemental Information


In compliance with 44 U.S.C. 3507, FDA has submitted the following proposed collection of information to OMB for review and clearance.

Antiparasitic Drug Use and Antiparasitic Resistance Survey—21 CFR 514.4 (OMB Control Number—0910-NEW)

Resistance of parasites to one or more of the major classes of FDA-approved antiparasitic drugs is a documented problem in cattle, horses, sheep, and goats in the United States. The results from this survey will provide FDA information that can be used to make decisions about future approaches to antiparasitic drugs. FDA will make the results of the survey publicly available.

FDA's Center for Veterinary Medicine (CVM) plans to survey members of veterinary professional organizations using an Internet-based survey instrument. The questions in the survey are designed to elicit professional opinions regarding the use of antiparasitic drugs and the awareness of antiparasitic drug resistance. The survey will query subjects on topics including: (1) Awareness of the issues related to antiparasitic drug resistance; (2) methods currently being used to detect and/or monitor for antiparasitic drug resistance; (3) management practices being used or recommended to manage or reduce antiparasitic drug resistance; and (4) labeling and marketing considerations for antiparasitic drugs.

In the Federal Register of December 3, 2012 (77 FR 71603), FDA published a 60-day notice requesting public comment on the proposed collection of information. FDA received several comments in response to the notice, which are discussed below.

(Comment) The first comment stated that the collection is not necessary for the proper performance of FDA's functions.

(CVM Response) We disagree. The mission of the Office of New Animal Drug Evaluation within CVM is to expeditiously approve safe and effective, properly labeled, quality manufactured new animal drugs through a science-based approach in a regulatory environment. This collection is necessary for the proper performance of FDA/CVM's mission because it will help us gather information that can be used to appropriately label antiparasitic drugs and, thereby, enhance the sustainability and continued availability of approved antiparasitic drugs.

(Comment) Another comment stated that while assessing the current situation in the field is important, the information to be gained from the survey will have little practical utility because the data will be of opinions held by an extremely small sample size.

(CVM Response) The target population for this survey is the subset of veterinarians and parasitologists who have a direct opportunity to observe and assess the antiparasitic resistance issues in the field. CVM understands that a part of the target population, namely Start Printed Page 38038veterinarians with training and experience with large animals, are diminishing in numbers in some areas of the United States (​KB/​Resources/​Reference/​Pages/​Food-Supply-Veterinary-Medicine-Data-Maps.aspx). While a wider and more general sampling of veterinarians would provide a larger sample size, such sampling would then include those who have opinions on the topic of antiparasitic resistance but not direct experience with the animal populations of interest. CVM designed the survey with input from subject matter experts, statisticians, and epidemiologists to reach the largest and most representative sample of this target population. Sample size, as well as total survey error, was considered in the design.

(Comment) One comment stated that there are numerous variables involved in the field; thus, measuring resistance by observational methods has questionable validity. Re-infection is a significant confounder which could mimic resistance. Resistance should be determined more scientifically, such as through a challenge model.

(CVM Response) The survey is not designed to measure antiparasitic resistance but to collect information from clinical experts who diagnose and treat the relevant animal populations and to provide a basis to assist in the design of labeling for approved antiparasitic drug products and the design of educational outreach programs. Data from laboratory-based, experimental models is extremely important for characterizing antiparasitic resistance. For successful translational research, both “bench” research, such as challenge models, and research from clinical or field settings, such as collecting the observations of clinicians treating and monitoring real animal patients are needed (​scripts/​animaldrugsatfda/​details.cfm?​dn=​045-578).

(Comment) One comment stated that many antiparasitic drugs are available as over-the-counter drugs. Inappropriate or inconsistent administration could produce a perceived resistance.

(CVM Response) CVM has not designed the survey to estimate the prevalence of resistance and agrees with the comment that the survey should not be used to draw conclusions about potential causes of resistance. The collection of such data would require a multiyear, multisite study of parasite resistance and antiparasitic drug use in multiple species in diverse geographic regions throughout the country. Such a study would be prohibitively expensive and complicated and is outside the scope of this survey. However, the survey is appropriately designed to gauge the level of awareness and concern about antiparasitic drug resistance issues among veterinarians using drugs in different clinical practice and production settings, as well as among academic parasitologists and scientists involved in drug research and development. In addition, the survey is designed to investigate methods currently used by veterinarians to detect, monitor, and manage parasites and antiparasitic drug resistance.

(Comment) Another comment suggested FDA's efforts regarding drug safety and efficacy are vital. The survey could potentially yield a small glimpse of conditions in the field; however, the information to be gathered seems to be an ill fit with postmarket surveillance as well as adverse event reporting.

(CVM Response) We agree that the survey should not attempt to obtain the same data as that obtained through postmarket surveillance and adverse event reporting. The survey is not designed to yield data or reports of adverse drug reactions, lack of effectiveness, or product defects which is obtained as part of postmarket surveillance. Information regarding the current state of awareness and concern about antiparasitic drug resistance issues in the field is important because it will assist CVM in the enhancement of appropriate labeling for the safe and effective use of approved antiparasitic drug products. The survey is one tool in a comprehensive antiparasitic resistance management strategy within CVM aimed at facilitating collaboration with CVM stakeholders on the issues related to antiparasitic resistance.

(Comment) Another comment stated that recommendations regarding the management or reduction of antiparasitic resistance are aspects of medical management and preventative herd health within the practice of veterinary medicine. Such recommendations are based upon veterinary expertise combined with several factors including animal owner capabilities, animal species and health, and the parasitic risks. The respondent questioned FDA's reasoning and intended regulatory use in gathering such information from responders, especially since such recommendations are available in scientific literature.

(CVM Response) The proposed survey is not intended as a replacement for the review of scientific research in published literature or the recommendations of expert veterinary parasitologists. As announced for the “Antiparasitic Drug Use and Resistance in Ruminants and Equines; Public Meeting; Request for Comments” (77 FR 7588, February 13, 2012; Docket No. FDA-2012-N-0102), CVM is committed to accessing and highlighting current research associated with the development and management of antiparasitic resistance in the United States. The survey is not designed to lead to any new recommendations regarding the management or reduction of antiparasitic resistance or provide recommendations related to the practice of veterinary medicine, but rather obtain information regarding the awareness and use of a variety of available strategies for detecting, monitoring, and/or managing antiparasitic resistance. CVM will not use the survey to undermine efforts of other organizations to provide science-based recommendations regarding the management or reduction of antiparasitic resistance. Instead, information obtained from the survey will be used to ensure properly labeled, safe, and effective antiparasitic drugs are available to veterinarians. In doing so, CVM will be providing the best array of options for veterinarians to choose from as they serve their patients and will be fulfilling its mission to protect human and animal health.

(Comment) Finally, one comment suggested that if a survey is to be done, it should be redesigned so that, while it may still gather opinions, it focuses on obtaining pertinent scientific information and more accurately targets respondents possessing the appropriate expertise on this particular subject. Also, that the incorporation of a scientific literature review may be beneficial in addressing some of the questions proposed.

(CVM Response) CVM believes that there are other more appropriate ways to obtain specific scientific information regarding antiparasitic resistance, such as holding public meetings, directly consulting with experts in the field of veterinary parasitology, and reviewing published literature available on the subject. As previously discussed, this survey is designed specifically to obtain information on the levels of awareness and concern related to antiparasitic resistance issues among veterinarians, key stakeholders for CVM.

FDA estimates the burden of this collection of information as follows:Start Printed Page 38039

Table 1—Estimated Annual Reporting Burden 1

Portion of studyNo. of respondentsNo. of responses per respondentTotal annual responsesAverage burden per responseTotal hours
Pre-test717.5 (30 minutes).3.5
Survey6501650.5 (30 minutes).325
1 There are no capital costs or operating and maintenance costs associated with this collection of information.

FDA calculated the total annual responses by multiplying the number of respondents by the annual frequency. FDA calculated the total hours by multiplying the estimated hours per response by the number of respondents.

Start Signature

Dated: June 27, 2014.

Leslie Kux,

Assistant Commissioner for Policy.

End Signature End Supplemental Information

[FR Doc. 2014-15648 Filed 7-2-14; 8:45 am]